hrp0089p3-p330 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P3 | ESPE2018

Gender Dysphoria

Lidwall Birgit , Fors Hans

Purpose: To assess the prevalence in 2017 and elucidate the well-being of youngsters with gender dysphoria.Background: Gender dysphoria is described as a strong and persistent feeling of being born in the wrong sex. Often the feeling is associated with impaired ability to function in everyday life, found in children, adolescents and adults. For adolescents with gender dysphoria, puberty is an additional mental strain that can lead to depression, anxiety ...

hrp0095p1-296 | GH and IGFs | ESPE2022

No differences in adult height outcome with personalized approach to Growth Hormone dosing– but gender differences were found

Ly Helena-Jamin , Fors Hans , Dahlgren Jovanna

Introduction: The goal of treating short children with growth hormone (GH) is to normalize adult height adjusted for mid parental height (MPH). We obtained adult height data on 87 patients (23 girls, 64 boys) treated with GH who originally participated in a randomized, prospective, open-label clinical trial with either personalized dose based on a prediction model (n=58), or standard dose (n=29). The children were either growth hormone defici...

hrp0084p1-115 | Puberty | ESPE2015

Clinical Guidance on 17β-Oestradiol and LH Serum Levels in Girls with Premature Thelarche Based on Clinical Outcome of 129 Girls Aged up to 4 Year with Premature Thelarche in West Sweden

Osterbrand Martin , Alvin Kerstin , Fors Hans , Norjavaara Ensio

Background: Simple clinical investigations to differ harmless premature thelarche (PT) from pubertal precocity and other pathological conditions are needed as PT is a common condition in girls under the age of 3–4 year.Objective and hypotheses: Since 17β-oestradiol (17β-E2) is the major driver of breast development, the hypothesis is, that it is possible to define an upper serum 17β-oestradiol (17β-E2) level for harmless PT in gi...

hrp0082fc3.3 | Diabetes | ESPE2014

Improved Hepatic Insulin Sensitivity in Children Randomized to CSII Treatment from Onset of Type 1 Diabetes

Ekstrom Klas , Skogsberg Lars , Fors Hans , Carlsson-Skwirut Christine , Bang Peter

Background: Our first report of this randomized controlled trial (RCT) demonstrated improved treatment satisfaction but no difference in HbA1c between the CSII and MDI treated groups, and added to the controversy as to whether CSII improves HbA1c or not. Therefore, we thought it would be valuable to assess if CSII had other potential advantages and if our finding of lower insulin dose requirements could be explained.Objective and Hypotheses: To study how...